GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (OTCPK:MDXXF) » Definitions » Change In Payables And Accrued Expense

MDXXF (Pharmala Biotech Holdings) Change In Payables And Accrued Expense : $0.24 Mil (TTM As of Feb. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Pharmala Biotech Holdings Change In Payables And Accrued Expense?

Pharmala Biotech Holdings's Change In Payables And Accrued Expense for the quarter that ended in Feb. 2024 was $0.11 Mil. It means Pharmala Biotech Holdings's Accounts Payable & Accrued Expense increased by $0.11 Mil from Nov. 2023 to Feb. 2024 .

Pharmala Biotech Holdings's Change In Payables And Accrued Expense for the fiscal year that ended in Aug. 2023 was $0.16 Mil. It means Pharmala Biotech Holdings's Accounts Payable & Accrued Expense increased by $0.16 Mil from Aug. 2022 to Aug. 2023 .

Pharmala Biotech Holdings Change In Payables And Accrued Expense Historical Data

The historical data trend for Pharmala Biotech Holdings's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings Change In Payables And Accrued Expense Chart

Pharmala Biotech Holdings Annual Data
Trend Aug21 Aug22 Aug23
Change In Payables And Accrued Expense
0.11 0.18 0.16

Pharmala Biotech Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.01 0.12 0.01 0.11

Pharmala Biotech Holdings Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmala Biotech Holdings Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmala Biotech Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (OTCPK:MDXXF) » Definitions » Change In Payables And Accrued Expense
Comparable Companies
XCNQ:ASEP XCNQ:PHRM XCNQ:COOL TSXV:QPT XCNQ:TELI TSX:AEZS XCNQ:BLAB NEOE:BMND TSXV:NRX TSXV:KNE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
MDMA:Canada
Address
82 Richmond Street East, Toranto, ON, CAN, M5C 1P1
Website
https://www.pharmala.ca
Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. PharmAla's drug API is manufactured and encapsulated under GMP conditions. The Company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations.